Federal judge rules in favor of Sanofi, Regeneron in patent suit over cholesterol drugs
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha.
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha.
With high price tags and a tougher path to generic as a biologic, payer pressure on clinicians to raise adherence for PCSK9 drugs to new heights will be keen.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.